[1]
A. . Armstrong, “Conjunctivitis Does Not Increase With Longer Duration of Lebrikizumab Exposure in Patients With Moderate-to-Severe Atopic Dermatitis”, J of Skin, vol. 7, no. 6, p. s276, Nov. 2023.